Firocoxib

As a selective cyclooxygenase-2 (COX-2) inhibitor belonging to non-steroidal anti-inflammatory drugs, firocoxib can specifically block the synthesis of prostaglandins mediated by COX-2 to achieve highly effective anti-inflammatory and analgesic effects, while greatly reducing the risk of gastrointestinal adverse reactions common to traditional non-steroidal anti-inflammatory drugs. In veterinary clinical practice, this drug is mainly used to relieve pain and inflammation caused by osteoarthritis in dogs, and can also be used for postoperative analgesia in dogs. It is one of the mainstream drugs in the field of anti-inflammatory therapy for companion animals at present, and has a broad clinical application foundation in the global pet medical market.

The global market size of veterinary firocoxib has maintained steady growth in recent years. In 2023, the market size was approximately USD 280 million, with a compound annual growth rate maintained at around 7%. The current market pattern is still dominated by original research products. Europe and North America are the core consumption regions, accounting for more than 65% of the total global demand. The domestic market is currently in the introduction period. With the consumption upgrade of pet medical care, especially the rising demand for diagnosis and treatment of osteoarthritis in elderly dogs, the market penetration rate of firocoxib is gradually increasing, and the layout progress of local generic drug enterprises is also accelerating.

The original research enterprise of firocoxib is Merck Sharp & Dohme, and the original trade name is "Previcox". Its core compound patent expired in the EU region in 2022, and the core patent in the US region expired in 2023. The main dosage form of the original research marketed product is chewable tablet, with two specifications of 57mg and 227mg, which has been listed as a veterinary reference listed drug by the FDA. As of the time of search, there is no approved firocoxib preparation for human use marketed in China. For veterinary preparations, only the original research product has been approved for import, and no enterprise has submitted a registration application for firocoxib API on the API registration platform of CDE. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of firocoxib impurity reference standards. Most products are in regular stock. Spot orders placed before 16:00 can be shipped on the same day. All products comply with the regulations of multiple countries such as the Chinese Pharmacopoeia and FDA, and can fully meet the compliance requirements of pharmaceutical enterprises at various stages of R&D, quality research and declaration.